The “Hard 20” in New Zealand Isn’t Just a Legal Detail—It’s the Clock That Decides Who Wins.
In drug development, timelines are everything. But in New Zealand, one timeline stands out—not because it’s dramatic, but because it’s unforgiving.
A hard 20-y…

Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…

Pharma has a tax problem—and a patent problem—and they’re now inseparable.
For years, life sciences leaders treated IP strategy and tax strategy as parallel tracks: build the patent estate, then optimize the tax outcome. But the “patent box” playbook—o…

180 Days: The Generic Launch Window That Can Make (or Break) Everything
In generic drug launches, timing isn’t just a schedule—it’s strategy, leverage, and risk management. And few deadlines carry as much weight as the 180-day exclusivity period under …

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Biopharma is in a talent race—and the winners will hire before the patents do.
Most people think the “patent-to-pipeline” timeline is about chemistry, filings, and regulatory strategy. It’s not. It’s about people—specifically, the people who can transl…

Russia’s biosimilar story is no longer a footnote—it’s a pipeline with momentum, and it’s starting to reshape oncology economics in ways many Western stakeholders are only beginning to notice.
Here’s the agitation: while the West debates incremental po…

Pharma’s “Pharm-to-Table” Promise Is Only as Strong as Its Supply Chain Intelligence
Drug shortages aren’t just a logistics problem. They’re a signal problem.
When a critical medicine disappears from shelves, the public sees the symptom—empty pharmacie…

The drug patent clock is ticking—most IP teams are forecasting it like it’s a calendar. It’s not.
In pharma, “patent expiry” is often treated as a single date on a spreadsheet. But the real timeline is a moving target shaped by prosecution history, pat…

Pharma’s next competitive edge won’t come from a new molecule—it will come from faster market entry intelligence.
For years, IP teams and pharma strategists have treated “market entry” like a downstream event: a filing here, a patent challenge there, a…